ArticleJournal of cheminformatics2025
Improving drug-induced liver injury prediction using graph neural networks with augmented graph features from molecular optimisation.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- MacroTox: A Macroscopic Graph Topology-Based Multimodal Learning Framework for Robust Molecular Toxicity Prediction.JACS Au · 2026Article
- Integrating multi-type features and knowledge graph for graded prediction of drug-induced liver injury in humans.PLoS computational biology · 2026Article
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- Predicting toxicity and bioactivity of the chemical exposome: a case study for the blood exposome database.Journal of cheminformatics · 2026Article
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
- A large-scale human toxicogenomics resource for drug-induced liver injury prediction.Nature communications · 2025Article
- Predicting Toxicity and Bioactivity of the Chemical Exposome: A Case Study for the Blood Exposome Database.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeDrug-induced liver injury (DILI) is a significant concern in drug development, often leading to the discontinuation of clinical trials and the withdrawal of drugs from the market. This study explores the application of graph neural networks (GNNs) for DILI prediction, using molecular graph representations as the primary input.
methodsWe evaluated several GNN architectures, including Graph Convolutional Networks (GCNs), Graph Attention Networks (GATs), Graph Sample and Aggregation (GraphSAGE), and Graph Isomorphism Networks (GINs), using the latest FDA DILI dataset and other molecular property prediction datasets. We introduce a novel approach that creates a custom graph dataset, driven by molecular optimisation, that incorporates detailed and realistic chemical features such as bond lengths and partial charges as input into the GNN models. We have named our model approach DILIGeNN.
resultsDILIGeNN achieved an AUC of 0.897 on the DILI dataset, surpassing the current state-of-the-art model in the DILI prediction task. Furthermore, DILIGeNN outperformed the state-of-the-art in other graph-based molecular prediction tasks, achieving an AUC of 0.918 on the Clintox dataset, 0.993 on the BBBP dataset, and 0.953 on the BACE dataset, indicating strong generalisation and performance across different datasets.
conclusionDILIGeNN, utilising a single graph representation as input, outperforms the state-of-the-art methods in DILI prediction that incorporate both molecular fingerprint and graph-structured data. These findings highlight the effectiveness of our molecular graph generation and the GNN training approach as a powerful tool for early-stage drug development and drug repurposing pipeline. Scientific Contribution: DILIGeNN is a GNN framework that extracts graph features from 3D optimised molecular structures as is done in target-based drug discovery and molecular docking simulation. Our method is the first to encode spatial and electrostatic information into a single graph representation, as opposed to other work that require multiple graphs or additional chemical descriptors for feature representation. Our approach, using warm starts following repeated early stopping during training, outperforms the current state-of-the-art methods in liver toxicity (DILI), permeability (BBBP) and activity (BACE) prediction tasks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.